DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline
Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM · Source last updated 2024-03-12
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline (Day 1) and up to 170 weeks
What was measured
Blood samples were collected for the analysis of following chemistry parameters: Hypoglycemia, hypoalbuminemia, alkaline phosphatase (ALP) increased, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatine kinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hyperkalemia, blood lactate dehydrogenase (LDH) increased, hypermagnesemia, hypomagnesemia, hypernatremia, hypercalcemia, hypocalcemia and Serum OR Plasma Glomerular Filtration Rate (GFR) from creatinine adjusted for body surface area (BSA) SA (mL/sec/1.73m\^2)/chronic kidney disease. The laboratory parameters were graded according to CTCAE version 5. G1: mild; G2: moderate; G3: severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2 and G3 are presented.
Analysis population: Safety Population included all participants who received at least 1 dose of any component of the combination therapy.
Groups in this outcome
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
Participants with RRMM received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 8 mg OX40 IV solution 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles.
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion as powder for solution Q3W infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 8 mg OX40 IV solution 1 hour after belantamab mafodotin EOI on day 1 of 21-day cycles.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
6
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
3
Reported measurements
Hypoglycemia, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypoglycemia, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypoglycemia, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
Hypoalbuminemia, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypoalbuminemia, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
2
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypoalbuminemia, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
ALP Increased, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
4
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
ALP Increased, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
ALP Increased, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
ALT Increased, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
ALT Increased, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
ALT Increased, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
AST Increase, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
4
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
AST Increase, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
AST Increase, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Blood bilirubin Increased, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Blood bilirubin Increased, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Blood bilirubin Increased, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
CPK Increased, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
2
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
CPK Increased, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
CPK Increased, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Creatinine Increased, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
3
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Creatinine Increased, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
Creatinine Increased, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
GGT Increased, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
3
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
GGT Increased, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
GGT Increased, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hyperkalemia, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
Hyperkalemia, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hyperkalemia, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
LDH increased, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
2
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
2
Not reported
Not reported
Not reported
Not reported
LDH increased, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
LDH increased, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypermagnesemia, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
Hypermagnesemia, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypermagnesemia, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypomagnesemia, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
Hypomagnesemia, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypomagnesemia, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypernatremia, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypernatremia, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypernatremia, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypercalcemia, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
Hypercalcemia, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypercalcemia, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypocalcemia, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypocalcemia, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Hypocalcemia, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
GFR from creatinine/Chronic Kidney Disease, Increase to G1
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
GFR from creatinine/Chronic Kidney Disease, Increase to G2
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
GFR from creatinine/Chronic Kidney Disease, Increase to G3
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
1
Not reported
Not reported
Not reported
Not reported
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
0
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Hypoglycemia, Increase to G1
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
Hypoglycemia, Increase to G2
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
title
Hypoglycemia, Increase to G3
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
title
Hypoalbuminemia, Increase to G1
categories
measurements
group Id
OG000
value
2
group Id
OG001
value
0
title
Hypoalbuminemia, Increase to G2
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
0
title
Hypoalbuminemia, Increase to G3
categories
measurements
group Id
OG000
value
4
group Id
OG001
value
0
title
ALP Increased, Increase to G1
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
1
title
ALP Increased, Increase to G2
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
ALP Increased, Increase to G3
categories
measurements
group Id
OG000
value
1
group Id
OG001
value
1
title
ALT Increased, Increase to G1
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
ALT Increased, Increase to G2
categories
measurements
group Id
OG000
value
0
group Id
OG001
value
0
title
ALT Increased, Increase to G3
denoms
counts
group Id
OG000
value
6
group Id
OG001
value
3
units
Participants
description
Blood samples were collected for the analysis of following chemistry parameters: Hypoglycemia, hypoalbuminemia, alkaline phosphatase (ALP) increased, alanine aminotransferase (ALT) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatine kinase (CPK) increased, creatinine increased, gamma glutamyl transferase (GGT) increased, hyperkalemia, blood lactate dehydrogenase (LDH) increased, hypermagnesemia, hypomagnesemia, hypernatremia, hypercalcemia, hypocalcemia and Serum OR Plasma Glomerular Filtration Rate (GFR) from creatinine adjusted for body surface area (BSA) SA (mL/sec/1.73m\^2)/chronic kidney disease. The laboratory parameters were graded according to CTCAE version 5. G1: mild; G2: moderate; G3: severe or medically significant. Higher grade indicates greater severity and an increase in CTCAE grade was defined relative to the Baseline grade. Any worst-case post baseline increase to G1, G2 and G3 are presented.
groups
description
Participants with RRMM received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 8 mg OX40 IV solution 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles.
id
OG000
title
1.9 mg/kg Belantamab Mafodotin + 8mg OX40
description
Participants with RRMM received 2.5 mg/kg belantamab mafodotin IV infusion as powder for solution Q3W infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 8 mg OX40 IV solution 1 hour after belantamab mafodotin EOI on day 1 of 21-day cycles.
id
OG001
title
2.5 mg/kg Belantamab Mafodotin + 8mg OX40
param Type
COUNT_OF_PARTICIPANTS
population Description
Safety Population included all participants who received at least 1 dose of any component of the combination therapy.
reporting Status
POSTED
time Frame
Baseline (Day 1) and up to 170 weeks
title
DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to Baseline
Triangle